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Methods: Three patients [PT1, F, 27 years old (yo) at last examination, 14-year follow-up (F/U) PT2, F, 15-
yo PT3, M, 15-yo, both 1-year F/U] underwent eye exams, Goldmann visual ﬁelds (GVFs), dark- (DA) and
light-adapted (LA) electroretinograms (ERGs), spectral domain optical coherence tomography (SD-OCT)
and fundus autoﬂuorescence (FAF). Vision and systemic history were also collected.
Results: All patients had night blindness, hyperopic astigmatism, ptosis or mild blepharospasm, foot pol-
ydactyly, 5th ﬁnger clinodactyly, history of headaches, and variable, diet-responsive obesity. Two had
asthma, PT1 was developmentally delayed, PT2 had Asperger-like symptoms, and PT3 had normal cogni-
tion. At age 14, acuity was 20/100 in PT1, who had nystagmus since age 2, 20/40 in PT2 and 20/30 in PT3.
By 27 yo PT1 progressed to 20/320, by 15 yo PT2 was 20/60 and PT3 remained stable. PT1 had well pre-
served peripheral GVFs, with minimal progression over 10 years of F/U. PT2 and PT3 presented with ring
scotomas and I4e < 5. All patients had severe generalized visual sensitivity depression. ERGs were con-
sistently recordable (also rod ERG in PT3 after 60 min DA), but progressed to non-recordable in PT1.
Mixed DA ERGs exhibited electronegativity. In PT3, this was partly due to a bleaching effect during
bright-ﬂash DA averaging, partly to ON OFF LA response compromise. PT2 and 3 had, on SD-OCTs, gen-
eralized macular thinning, normal retinal lamination, and widespread photoreceptor outer/inner seg-
ment attenuation except foveally, and multiple rings of abnormal FAF conﬁguring a complex bull’s
eye-pattern. PT1 had macular atrophy. All patients also had peripapillary nerve ﬁber layer thickening.
Conclusions: The observed phenotype matches very closely that reported in patients by Azari et al. (IOVS
2006) and in the Bbs1-M390R knock-in mouse model, and expands it to the characterization of important
ERG response characteristics that provide insight in the pathogenesis of retinopathy in these patients.
Our ﬁndings conﬁrm the consistent pathogenicity of the BBS1 M390R mutation.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
Bardet–Biedl syndrome (BBS) is a disorder characterized by ret-
inal degeneration and multiple systemic manifestations including
obesity, dystrophic extremities (polydactyly, syndactyly, brachy-
dactyly and/or clinodactyly), abnormalities of the genitourinary
tract including potentially life-threatening kidney dysfunction,ll rights reserved.
nessee Health Science Center,
, 930 Madison Ave., Ste. 731,
e).secondary sexual development problems (hypogonadism more of-
ten in males, but virilism reported also in females), varying degrees
of cognitive and behavioral abnormalities, and a host of other man-
ifestations including hyposmia (Iannaccone, 2005; Iannaccone
et al., 1997, 1999, 2005).
There are currently 17 identiﬁed genes which are involved in
the development of BBS (https://sph.uth.tmc.edu/retnet/sum-
dis.htm#B-diseases and Zhang, Yu, et al., 2012). To date, except
for a tendency of BBS1 patients to exhibit on average a relatively
milder phenotype than other forms of BBS (Azari et al., 2006; Dan-
iels et al., 2012), no unique human genotype–phenotype associa-
tion has emerged to permit differentiating BBS patients in
subtypes depending on the associated genetic defect except for
78 K.F. Cox et al. / Vision Research 75 (2012) 77–87cases of non-syndromic RP linked to BBS gene mutations (Pretorius
et al., 2010, 2011; Zhang, Nishimura, et al., 2012). This is likely due
in part to the fact that most BBS genes, as are many others involved
in retinal dystrophies, share the biological and disease-causing
mechanistic basis of causing ciliary dysfunction (Loktev et al.,
2008; Mykytyn & Shefﬁeld, 2004; Seo et al., 2010; Zhang, Yu,
et al., 2012). Although it has been proposed by some (Katsanis
et al., 2001) that BBS may not routinely follow a Mendelian autoso-
mal recessive inheritance pattern as traditionally believed, we and
others have previously investigated the frequency of mutations
other than the ones considered ‘‘primary’’ in BBS patients and
could not ﬁnd evidence to support the need for triallelism in BBS
(Mykytyn et al., 2003). The consistent phenotypic effects observed
in mice whose hortolog genes have been knocked out or that, sub-
sequently, had speciﬁc mutations like the BBS1 M390R one
knocked-in (Davis et al., 2007; Mykytyn et al., 2004; Swiderski
et al., 2007; Zhang, Nishimura, et al., 2012), conﬁrms that BBS re-
mains a Mendelian autosomal recessive disease. However, the
aforementioned biological and disease-causing mechanistic over-
lap amongmany BBS genes at the ciliary basal body makes the pos-
sibility of epistatic effects exerted on the main phenotypic
determinants by secondary mutations quite plausible and, surely
in some cases, highly likely (Badano et al., 2003).
BBS has been a key focus of the work of our group for nearly
two decades. Despite the wide genetic heterogeneity of BBS and
the elusiveness of genotype–phenotype correlations, it has been
reported that approximately 80% of the Caucasian patients with
BBS1 carry the M390R mutation within the BBS1 gene, which is
also the most common gene involved in BBS (Mykytyn et al.,
2002). The M390R mutation alone accounts for approximately
27% of all cases of BBS (Shefﬁeld, Nishimura, & Stone, 2012,
unpublished observation). Therefore, there is much value in
understanding the phenotypic effects in humans of this speciﬁc
mutation for the BBS research ﬁeld. In recent years, mouse mod-
els for BBS have been developed, including one in which the
Bbs1 M390R mutation has been knocked in (Davis et al., 2007),
and preclinical gene transfer and pharmacologic therapies have
shown a great deal of potential for achieving successful treat-
ment of BBS (Drack et al., 2011; Simons et al., 2011). Among
these, and of particular relevance to this manuscript, was the
beneﬁt observed with TUDCA supplementation in the aforemen-
tioned Bbs1-M390R knock-in mice on both the retinal and the
obesity phenotype (Drack et al., 2011). To the best of our knowl-
edge, only one previous paper has documented in detail the clin-
ical, microanatomical, and functional phenotypic expression of
BBS1 patients (Azari et al., 2006).
The growing understanding of BBS pathophysiology, the pros-
pect of treatments becoming potentially available in the near fu-
ture, and the availability of three patients homozygous for the
common M390R BBS1 mutation prompted us to conduct a retro-
spective investigation of their phenotypic presentation. Herein
we will illustrate how the retinal phenotype linked to homozygos-
ity for the M390R BBS1mutation exhibits remarkable homogeneity
with the previously reported one (Azari et al., 2006), while display-
ing variability at the systemic end. We will provide additional evi-
dence for impaired post-receptoral function consistently affecting
the retinas of these patients, as well as evidence for defective visual
pigment recycling. Our data both corroborate previous ﬁndings
(Azari et al., 2006) and expand our understanding of the pheno-
typic expression of BBS linked to the common M390R BBS1 muta-
tion. Furthermore, our data offered us the possibility to draw a
parallel with the retinal phenotype exhibited by Bbs1-M390R
knock-in mice, showing how this model reproduces closely human
disease expression and allowing us to gain insight in the pathogen-
esis of human retinal disease.2. Materials and methods
2.1. Subjects
Three previously unreported patients with BBS were included in
this retrospective investigation. Basic demographics of the three
patients are reported in Table 1. The genotype was ascertained
via molecular genetic diagnostic testing performed by the Carver
Lab at University of Iowa. After obtaining informed consent for
testing, genomic DNA was extracted from whole blood samples
collected from the probands and their parents and PCR-ampliﬁed
according to standard procedures. Probands were tested with the
targeted BBS diagnostic screening panel currently offered by the
Carver Lab, aimed at determining if they carried either the com-
mon BBS1 Met390Arg (M390R) or the common BBS10 Leu90 ins 1
T mutations. All three patients were found to be homozygous for
the common BBS1 M390R mutation, and parental sample analyses
conﬁrmed that each allele was carried in the heterozygous state by
each asymptomatic parent.
Each patient was interviewed with a standardized question-
naire to collect detailed information of type, age of onset, severity
and progressive nature of visual symptoms. Systemic manifesta-
tions were also documented in detail by history as well as by phys-
ical observation and examination.
All subjects underwent clinical ocular examinations including
determination of best corrected visual acuity with standard ETDRS
charts, assessment of ocular adnexa and motility, anterior and pos-
terior segment slit lamp examination, imaging studies inclusive of
color fundus photography and spectral domain optical coherence
tomography (SD-OCT) of the macula and disk (see Supplemental
Methods section for additional information). High-resolution, 30
cross sectional SD-OCT images of the macula intersecting the fo-
veal dip were obtained from PT2 and PT3. At the latest examina-
tion, images were also obtained with enhanced depth imaging
(EDI) methodology, as described by Spaide, Koizumi, and Pozzoni
(2008). PT2 and PT3 had retinal nerve ﬁber layer (RNFL) thickness
measured with the standard optic disk cube protocol of the Cirrus
SD-OCT (Zeiss Meditec, Dublin, CA). In addition, cross sectional SD-
OCT images were obtained for the optic nerve of PT3 along with
custom RNFL thickness measurements (Supplemental Methods
and Figure). Fundus autoﬂuorescence (FAF) images could also be
obtained on PT3 (Supplemental Methods). PT1 and PT2 experi-
enced too much light aversion to undergo FAF with this methodol-
ogy. PT1 experienced also an excessive amount of nystagmus and
had inadequate ﬁxation to permit obtaining reliable SD-OCT scans
of sufﬁcient quality for further analysis.
Visual function studies included Goldmann visual ﬁelds (GVFs),
full-ﬁeld ﬂash electroretinograms (ERGs) and, when possible, auto-
mated monochromatic light- and dark-adapted perimetry. GVFs
performed with a minimum of two targets (V4e and I4e) as previ-
ously reported (Iannaccone et al., 2004, 2006, 2008). See Supple-
mental Methods for speciﬁc details on GVF ﬁeld size calculations.
The calculated net ﬁeld area was compared to our published nor-
mative data (Iannaccone et al., 2004), and expressed as percent
of the lowest limit of these normal ranges. Flash ERGs were
performed in all subjects with an Espion2 and, more recently, an
Espion3 system (Diagnosys LLC, Lowell, MA, USA) at baseline and
at follow-up examinations with monopolar corneal electrodes
(ERG-Jet, Universo Plastique AS, Grenchen, Switzerland) as previ-
ously reported (Iannaccone et al., 2006). Responses were recorded
at various points in time on PT1 during the 15-year follow-up
period, initially also with a Nicolet Spirit system (Viasys Nicolet
Biomedical, Madison, WI, USA). Additional ERG methodology
details are provided in the Supplemental Methods section. The
amplitude (in lV) of the a- and b-waves were compared to the
Table 1
Clinical characteristics of our BBS1 patients homozygous for the M390R mutation.
Characteristic Patient
PT1 PT2 PT3
Age (ﬁrst/last examination) 12/27 yo 14/15 yo 14/15 yo
Gender F F M
Symptoms of onset (age) Nystagmus (2 yo) Reduced VA (3 yo) Peripheral vision
loss (1 yo)
Night blindness
(3 yo)
Night blindness
(7 yo)
Night blindness
(5 yo)
Best corrected visual acuity OD OS OD OS OD OS
– First examination 20/60 20/80 20/50+2 20/322 20/50 20/40
– Last examination 20/320 20/400 20/60+1 20/40+1 20/60 20/80
Refraction +1.50 + 3.25  105 +1.00 + 3.00  085 +1.75 + 2.00  075 +0.50 + 3.50  110 +2.00  1.25  180 +1.00  1.50  180
Eyelids Dermatochalasis
mild ptosis
Dermatochalasis
moderate ptosis
Mild
blepharospasm
Mild
blepharospasm
Mild ptosis Mild ptosis
Post. subcapsular cataract Axial, dense Axial, dense None None None None
Goldmann visual ﬁeld (age) 18/25 yo 14/15 yo 14/15 yo
– First examination (V4e/I4e) 69%, 0% 75%, 0% 51%, <1% 47%, <1% 84%, <0.1% 100%, <0.1%
– Last examination (V4e/I4e) 67%, 0% 64%, 0% 55%, 0% 50%, 0% 89%, <0.1% 91%, <0.1%
Flash ERGs (last examination)
– DA rod 0.08 cd s/m2 N/R N/R N/R N/R N/R 30’, 25% 60’ N/R 30’, 28% 60’
– DA mixed 2.1, 10.0 cd s/m2 N/R N/R a-w: 7%, 13% a-w: 6%, 5% a-w: 34%, 23% a-w: 27%, 32%
b-w: 5%, 3%a b-w: 5%, 5%a b-w: 34%, 16%a b-w: 34%, 16%a
– LA cone 2.1, 10.0 cd s/m2 N/R N/R b-w: 22%, 28% b-w: 15%, 22% b-w: 21%a, 36% b-w: 18%a, 28%
– LA ﬂicker 2.1, 10.0 cd s/m2 N/R N/R 15%, 15% 12%, 15% 26%, 38% 21%, 35%
Our normative data range (95th conﬁdence interval around the mean) for the 10 (+1.0 log) cd s/m2 stimuli amplitudes and timing are: DA mixed a-wave: 250–387 lV, 11.0–
15.3 ms; DA mixed b-wave: 346–571 lV, 38.3–51.3 ms; LA cone b-wave 96–196 lV, 27.0–34.8 ms; LA ﬂicker peak: 104–218 lV, 28.2–33.4 ms.
a Electronegative ERG b-wave.
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and expressed as percentages of these limits. Our normative data
for these stimulus conditions (95% conﬁdence intervals around
the mean) have been previously published (Iannaccone et al.,
2006) except for the 10(1.0 log) cd s/m2 stimuli, which are re-
ported herein.
In addition to these standard recordings, because of suspicion of
a bleaching effect causes by the bright ﬂashes in the DA state sug-
gestive of defective recycling of the visual pigments (see below,
Section 3), rod-driven ﬂash ERGs were also obtained in PT3 after
prolonged DA (60 min). To ascertain further the relative degree
of impairment of post-receptoral responses originating from ON-
and OFF-cone bipolar cells, photopic ON–OFF ERGs were also re-
corded in PT3 in response to 125-ms square-wave stimuli (Khan
et al., 2001; Sieving, 1993; Sieving, Murayama, & Naarendorp,
1994) alternating at a 4.5-Hz frequency and to rapid-ON and ra-
pid-OFF, 8.5-Hz saw-tooth stimuli (Alexander, Barnes, & Fishman,
2001), both presented on a bright LA background of 150 cd/m2.
PT2 was unable to undergo ON–OFF photopic ERGs due to exces-
sive light aversion. The responses of PT1 were too small to permit
this additional level of investigation.3. Results
Some of the salient demographic, clinical and functional ﬁnd-
ings for our three BBS1 patients homozygous for the M390R muta-
tion are summarized in Table 1. In brief, all patients experienced
night blindness at onset, which developed between 3 and 7 years
of age. All three subjects also had congenital polydactyly, history
of headaches and variable, diet-responsive obesity. Further details
about the phenotypic ﬁndings observed in each of these three sub-
jects are described in the following sections and are illustrated in
Figs. 1–4. Once evaluated at baseline, each patient was counseled
to the potential beneﬁts and limitations of vitamin A palmitate, lu-
tein, and DHA supplementation in RP, with the caveat that no BBS
patient and no children had been included in the trials that re-
ported reduced disease progression in association with these sup-plements (Berson et al., 1993, 2004a, 2004b, 2011). All subjects
took, at least in part (see below), these supplements. Therefore, fol-
low-up data has to be intended not as the natural history of disease
progression in these three patients, but the changes experienced
during such dietary supplementations.3.1. Patient 1 (PT1)
PT1 was ﬁrst seen at the age of 12 years old. In addition to early
onset night blindness, PT1 also had history of nystagmus noted
since age 2. She exhibited the most severe manifestations of the
three patients, both systemically and ophthalmically. Systemic fea-
tures included marked developmental delay, truncal obesity
(Fig. 1A) and post-surgical polydactyly with clinodactyly of the
5th ﬁnger (Fig. 1C). She took 15,000 IUs of vitamin A palmitate sup-
plements daily from age 12 until present, followed by the addition
of lutein 20 mg/day as of age 18 and ﬁsh oil supplements contain-
ing an equivalent daily DHA dose of 1000 mg since age 23. No liver
function or other systemic problems were reported during this per-
iod of supplementation.
Upon eye examination, visual acuity was 20/60 OD and 20/80
OS at baseline and was 20/320 OD and 20/400 OS at the latest
exam, showing a progressive decrease over the 15-year follow-up
(Table 1), only in part explained by the development of bilateral
axial dense subcapsular cataracts. She also had bilateral superior
eyelid dermatochalasis with mild left ptosis (Fig. 1B). Fundus
examination demonstrated central macular atrophy noted at age
18 (Fig. 2A) which progressed to an additional ring of bull’s eye
maculopathy at age 25 (Fig. 2B). Progressive RPE atrophy at the ar-
cades and mid-periphery alongside modest bone spicule-like intra-
retinal deposits were also apparent (Fig. 2A and B). Despite the
overall severity of her macular disease and its progressive nature,
by GVF criteria, PT1 had fairly well preserved peripheral visual
ﬁelds limits, though markedly depressed in peripheral sensitivity.
The superior visual ﬁeld defect may have resulted from both her
blepharochalasis and ptosis (the patient could not tolerate eyelid
taping) and greater severity of inferior retinal pathology. There
Fig. 1. Systemic and external manifestations. PT1: (A) marked obesity with a
prevailing truncal distribution (BMI: 33.7). (B) Dermatochalasis of both upper
eyelids and mild asymmetric ptosis (OS > OD). (C) Clinodactyly of the 5th ﬁnger
associated with skin scarring following surgical removal of supernumerary 6th
ﬁnger of the right hand (arrow). PT2: (D) sequelae of surgical correction of
syndactyly and polydactyly of the left hand, and clinodactyly of the 5th ﬁnger
(arrows). (E) Small lateral scars following surgical removal of bilateral polydactyly
of the feet (arrows), relative brachydactyly of the 5th toes, and mild leg hirsutism
(asterisk). PT3: Sequelae of surgical correction of polydactyly of the left (F) and right
(G) foot. (H) Mild clinodactyly of the 5th ﬁnger.
Fig. 2. En-face imaging ﬁndings. PT1: (A) fundus composite of OD at age 18
showing waxy pallor of the disk, vascular attenuation, macular RPE atrophy, diffuse
mid-peripheral RPE dropout with partial choroidal visualization, and rare mid-
peripheral intraretinal pigmentary deposit (inferonasal quadrant). (B) Fundus
composite of OD at age 25 showing increase in macular RPE atrophy, disk pallor
and RPE dropout also at the arcades. A faint bull’s eye pattern of perifoveal RPE
dropout can also be appreciated. PT2: Fundus composite of OD (C) and OS (D) at age
15 presenting with full, waxy pale disks, vascular attenuation, macular RPE dropout,
diffuse mid-peripheral RPE dropout with choroidal visualization in the inferior
quadrants, where also a few intraretinal punctate pigmentary deposits can be seen.
In OS, a nummular area of discrete RPE atrophy can also be seen inferonasal to the
disk. PT3: (E) fundus composite of OS at age 15 showing a full, mildly hyperemic
disk surrounded by a pale halo, focal macular RPE dropout, mid-peripheral RPE loss
and coarse mottling both superiorly and inferiorly with pronounced choroidal
visualization in the inferior quadrants. No intraretinal pigment deposits are
apparent. (F) Fundus autoﬂuorescence (FAF) at age 15, showing (a) loss of
autoﬂuorescence (AF) around the disk consistent with peripapillary RPE loss and
(b) a complex bull’s eye-like pattern in the macular region characterized by
multiple concentric rings of abnormal AF: an ill-deﬁned, irregularly shaped ring of
hyper-AF around the macula surrounds a wide parafoveal halo of hypo-AF within
which there is a tight perifoveal ring of near-normal AF, surrounding a focal foveal
area of marked hypo-AF, consistent with the subfoveal RPE dropout noted clinically.
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follow-up period (Fig. 3A, B and Table 1). However, consistent with
increasing macular disease progression, slight contraction of the
central area of I4e detection was seen. ERGs were ﬁrst performed
at age 15 and demonstrated marked delayed responses, albeit still
clearly recordable (Fig. 4). At age 17, transient electronegativity in
the mixed ERG responses was observed (not shown) and by age 25,
ERGs became non-recordable. FAF, SD-OCTs and ON–OFF LA ERGs
could not be performed on this patient.3.2. Patient 2 (PT2)
PT2 was ﬁrst seen at the age of 14 and has 1 year of follow-up
data. Night blindness was ﬁrst noted at 7 years of age. Systemic
features included diet-responsive truncal obesity (latest BMI:
27.4, before diet and exercise: 34), syndactyly and polydactyly of
the left hand (surgically corrected) and clinodactyly of the 5th digit
of the left hand (Fig. 1D). She also had bilateral polydactyly of the
feet (surgically corrected), relative brachydactyly of small toes, and
mild hirsutism of both legs (Fig. 1E). After the initial examination,
she started taking 15,000 IUs/day of vitamin A palmitate, lutein
20 mg/day, and ﬁsh oil supplements containing an equivalent daily
DHA dose of 1000 mg. No liver function or other systemic
problems have been reported during this short period of
supplementation.
Visual acuity was 20/50+2 OD and 20/322 OS at baseline exam-
ination and declined at the last two examinations to 20/60+1 OD [a
6-letter, or 0.12 logMAR change, which is signiﬁcant for undilated
acuity measurements in RP patients (Grover et al., 1997)] and 20/
40+1 OS (Table 1). The lens was clear bilaterally and fundusexamination demonstrated (Fig. 2C and D) macular and diffuse
peripheral RPE dropout bilaterally, the latter more pronounced
inferiorly with a coarse moth-eaten appearance and, in OS, a dis-
crete area of nummular RPE atrophy infero-nasal to the disk, mark-
edly attenuated retinal vasculature, and waxy pale, full disks. Only
a few intraretinal pigment deposits, mainly punctate in appear-
ance, were seen in the inferior quadrants. These clinical ﬁndings
did not change during follow-up. Macular and RNFL SD-OCT
(Fig. 5A and B) showed generalized thinning of the neural retina
with well-preserved retinal lamination, markedly attenuated
photoreceptor outer/inner segment (PR-OS/IS) junction and of the
outer nuclear layer (ONL) with relative foveal sparing, and thick-
ened rather than thinned RNFL by Cirrus SD-OCT criteria. FAFs
could not be performed reliably on this patient secondary to light
aversion.
GVFs were characterized by overall superior > inferior visual
ﬁeld loss and full, absolute ring scotomas with a large island of
peripheral vision in the inferior farthest hemiﬁeld (Fig. 3C). Over
the 1-year follow up (Fig. 3D), GVFs showed loss of central sensitiv-
ity from baseline (I4e no longer detected, central isopter delimited
Fig. 3. Patterns of Goldmann visual ﬁeld loss. PT1: Representative GVFs from OS at age 18 (A) and at age 25 (B) demonstrate superior > inferior ﬁeld loss, generalized
sensitivity depression, and essentially neither qualitative nor quantitative change over time. No scotomatous areas could be detected in the mid-periphery (not shown). PT2:
Representative GVFs from OD at age 14 (C) and age 15 (D): similar to PT1, there is overall greater superior visual ﬁeld loss; however, the pattern of disease expression differs,
with absolute mid-peripheral ring scotomas separating the central ﬁeld from a large island of peripheral vision in the farthest part of the inferior hemiﬁeld. During the short-
term follow-up period, there was no signiﬁcant change peripherally, but there was evidence of loss of central sensitivity from baseline (I4e no longer detected at age 15, only
the II4e target could be detected centrally). PT3: Representative GVFs from OS at baseline (age 14, E) and at age 15 (F) demonstrate overall preservation of the peripheral
limits to the V4e target, pericentral scotomas of variable density at baseline, progressing to an absolute ring scotoma in only 1 year. This change was associated also with
short-term loss of both peripheral (III4e) and central (I4e) sensitivity, and with a tightening of the pericentral scotoma around ﬁxation. These ﬁndings parallel closely the
ophthalmoscopy and FAF ﬁndings illustrated in Fig. 2.
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Fig. 4. Standard and custom baseline dark- (DA) and light-adapted (LA) electroretinogram (ERG) responses. Top row, normal example of a series of standard responses for our
lab, including DA rod-driven (0.008 cd s/m2, or 2.1 log cd s/m2), DA mixed rod-cone [2.1(+0.32 log) and 10(+1.0 log) cd s/m2], LA cone transient [2.1(+0.32 log) and
10(+1.0 log) cd s/m2], and cone ﬂicker [2.1(+0.32 log) cd s/m2] ERG responses. Second row, PT1: ERGs at age 15: DA rod-driven and mixed rod-cone ERGs were markedly
diminished and delayed but still recordable. LA cone-driven transient and ﬂicker ERGs were also markedly diminished and extremely delayed but still recordable. No
electronegativity was observed at this stage, but this feature became apparent in the mixed response subsequently (not shown), followed by diminution of the responses
below the recordable threshold (not shown). Third row, PT2: DA rod-driven ERGs are barely detectable. DA mixed rod-cone ERGs were clearly measurable, though diminished
and delayed, and they showed disproportionate b-wave reduction (arrows) compared to the a-wave. LA Cone-driven transient and ﬂicker showed delayed and decreased
amplitude responses with relatively normal b-wave shape. However, the a-wave was square-shaped, and there was selective reduction of the b-wave response (ON-
mediated) compared to the ensuing d-wave (OFF-mediated), indicating ON > OFF post-receptoral compromise. Fourth and ﬁfth row, PT3: Standard 30-min DA rod-driven
ERGs were non-recordable, whereas after 60-min DA they were delayed yet clearly recordable. The averaged DA mixed responses showed progressively more b-wave
truncation with increasing ﬂash intensity. Breaking down the 10(+1.0 log) cd s/m2 response to single ﬂashes, the response to the ﬁrst ﬂash (in orange) exhibited no
electronegativity, whereas all others did. Besides being delayed and reduced in amplitude, also LA responses were electronegative in response to the 2.1(+0.32 log) cd s/m2
stimulus, which was not due to a phenomenon similar to that seen for DA ones (not shown). Therefore (inset within the bottom row in the LA section), ON–OFF ERGs were
recorded from PT3 (top row within the inset). Compared to a normal example (bottom row of responses within the inset), responses showed ON-driven b-wave
electronegativity (arrows) and abnormal plateaus following the b-wave (asterisk) to both square wave and rapid-ON ramp stimuli. Unlike these, responses to both square
wave and rapid-OFF ramp stimuli were delayed and mildly reduced but otherwise overall normal in shape.
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for the better) in terms of peripheral ﬁeld size. The DA rod-driven
and mixed rod-cone ERGs and LA cone-driven ERGs were all
markedly reduced and markedly delayed but readily recordable.Moreover, the mixed ERG response showed disproportionate
b > a-wave reduction bilaterally (see arrows, Fig. 4). ON–OFF LA
ERGs could not be performed reliably on this patient secondary
to light aversion.
Fig. 5. Spectral domain optical coherence tomography (SD-OCT) ﬁndings. PT2: Transfoveal horizontal Spectralis EDI SD-OCTs (A) show generalized thinning of the neural
retina, markedly attenuated photoreceptor outer/inner segment (PR-OS/IS) junction with a good residue only in the foveal region, yet well deﬁned retinal lamination in both
eyes, as well as an epiretinal membrane characterized by retinal surface wrinkling in OD > OS; (B) Cirrus peripapillary RNFL SD-OCT showed RNFL thickening in several
quadrants (pie slices labeled in white) and normal RNFL thickness elsewhere (green pie slices) in both eyes. PT3: Horizontal and vertical transfoveal Spectralis EDI SD-OCTs
(C) of the left eye show mildly thinned neural retina, moderately attenuated PR-OS/IS junction in the peripheral portions of the scans but good preservation thereof
throughout the remainder of the scan, except that the foveal residue presents signiﬁcant irregularities; retinal lamination is very well preserved, and modest and focal
thickening of the vitreoretinal interface can be also appreciated. Horizontal and vertical transpapillary Spectralis SD-OCTs of the same eye (D) show swollen disk devoid of
physiologic cupping, thickened RNFL, and the incidental ﬁnding of a small epipapillary residue of the hyaloid vasculature and some epipapillary vitreal debris. Please refer to
Supplemental Figure for further details about the RNFL ﬁndings in PT3. Findings were comparable in the right eye (not shown). (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)
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PT3 was ﬁrst seen at the age of 14 and again at the age of 15.
Night blindness was experienced by this patient at 5 years of age.
Systemic features included diet-responsive obesity (BMI on diet
and exercise: 28.2, latest BMI after discontinuation of regimen:
29.4), bilateral polydactyly of the feet which was surgically cor-
rected (Fig. 1F and G, arrows) and clinodactyly of the 5th digit of
the right hand (Fig. 1H). After the initial examination, he started
taking 15,000 IUs/day of vitamin A palmitate, lutein 20 mg/day,
and ﬁsh oil supplements containing an equivalent daily DHA dose
of 1000 mg. Shortly after beginning supplementation, PT3 experi-
enced signiﬁcant worsening of his preexisting history of head-
aches. Serial disk SD-OCTs were also obtained during this period
with both the Cirrus and the Spectralis instruments, and custom
RNFL thickness measurements were performed at several locations
around the disk on SD-OCT scans intersecting the optic nerve head
(see Supplemental Figure). The standard circular scan of the Cirrus
SD-OCT failed to reveal RNFL thickening in this patient. However,
when compared to measurements at matching locations from
scans obtained from a normal subject, custom RNFL thickness mea-
surements made on the Spectralis scans immediately around the
lamina cribrosa opening demonstrated a signiﬁcant difference be-
tween the thickness of the RNFL in PT3 compared to normal on
both the vertical and horizontal axis (p = 0.007 and 0.03, respec-
tively, Student’s paired two-tailed T-test). Out of concern for a pos-
sible adverse effect of vitamin A on intracranial pressure, thissupplement was discontinued, which led to a resolution of the
complaint. No other side effects were reported during the 1-year
follow-up while on the other supplements. Serial Spectralis SD-
OCTs showed a restoration of the physiological disk cupping after
vitamin A discontinuation, which suggested that, in this patient,
the use of vitamin A may have contributed to an increase in intra-
cranial pressure and disk swelling, but the increased RNFL thick-
ness surrounding the disk persisted at subsequent examinations
(see Supplemental Figure), consistent with RNFL thickening also
in this patient being independent of vitamin A use.
Visual acuity was 20/50 OD and 20/40 OS at baseline examina-
tion and 20/60 OD and 20/80 OS at last examination. The lens was
clear bilaterally and fundus examination demonstrated macular
and peripheral RPE atrophy, leading to visualization of the under-
lying choroidal vasculature (Fig. 2E). FAF revealed multiple, macu-
lar bull’s eye-like and peripheral rings of increased and decreased
AF with superior and inferior RPE loss (Fig. 2F). Macular and disk
SD-OCT showed thinned neural retina, markedly attenuated PR-
OS/IS junction with fair foveal residue, preserved retinal lamina-
tion, and swollen disks with thickened RNFL (Fig. 5C and D). GVFs
at baseline showed marked depression in peripheral sensitivity yet
essentially full-size ﬁelds with pericentral scotomas that pro-
gressed to an absolute ring scotoma, tighter around ﬁxation, after
the 1-year follow-up (Fig. 3D and E). No ﬁeld expanse loss was ob-
served over this period, but central sensitivity appeared reduced
compared to baseline. The bottom two rows of Fig. 4 illustrate
the ERG responses of PT3, who had the best preserved responses
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after a standard period of 30 min of dark adaptation. Mixed DA
rod-cone responses demonstrated electronegativity resulting from
b-wave depression that increased with brighter ﬂash intensities in
the averaged responses. However, unaveraged single-ﬂash re-
sponses to 10.0 cd s/m2 ﬂashes showed a large b-wave in response
to the ﬁrst ﬂash (Fig. 4, bottom row, orange trace), followed by a
series of responses with much smaller b-waves. Except for a mod-
estly faster b-wave peak time to ensuing ﬂashes, this phenomenon
in our hands is never observed in normal subjects, but is closely
reminiscent of what patients with fundus albipunctatus (FA) and
retinitis punctata albescens (RPA) can show (Fishman et al.,
2004; Iannaccone et al., 2007). This ﬁnding raised the suspicion
of a bleaching effect caused by the bright ﬂashes in the DA state,
suggestive of defective recycling of the visual pigments. To test this
hypothesis, rod-driven ﬂash ERGs were also obtained in PT3 after
prolonged dark adaptation (60 min, Fig. 4, bottom row, left-hand
column). Consistent with our suspicion, a rod-driven response
could be clearly recorded after 60 min in the dark, albeit markedly
reduced. The LA cone ERGs were markedly reduced in amplitude
and delayed. The transient LA cone ERG responses demonstrated
also electronegativity. This ﬁnding, alongside the electronegativity
of ERG responses observed also in PT2 and, transiently, in PT1
suggested that BBS1 patients with the M390R mutation may
experience abnormal post-receptoral intraretinal signal process-
ing. To ascertain further the relative degree of impairment of
post-receptoral responses originating from ON- and OFF-cone
bipolar cells, photopic ON–OFF ERGs were recorded (Fig. 4, top ser-
ies of responses in the orange inset). ON–OFF LA ERGs exhibited
several abnormalities. The ON-driven b-wave to both square-wave
stimuli and saw-tooth was markedly depressed and delayed
(arrows) compared to normal (Fig. 4, bottom series of responses
in the orange inset). These waveforms were followed by abnormal
plateaus (asterisks) that are not usually observed in normal
responses. Unlike ON responses, OFF responses were somewhat
reduced in amplitude but were for the most part normal in shape
and timing, indicating that ON-bipolar cell activation was preemi-
nently compromised.4. Discussion
Phenotypic manifestations of BBS1 (M390R genotype) have be-
come increasingly well documented in recent years (Azari et al.,
2006; Deveault et al., 2011). Our investigation conﬁrmed many
of the ophthalmic, and speciﬁcally retinal, clinical and functional
features exhibited by BBS1 patients, found consistent, conﬁrma-
tory evidence for an effect of this genotype of post-receptoral ret-
inal function, and revealed also novel ﬁndings.
From a systemic standpoint, all patients had abnormal extrem-
ities (foot polydactyly and 5th-ﬁnger clinodactyly was seen in all),
history of headaches, and variable obesity, which was diet-respon-
sive in PT2 and PT3. These ﬁndings are similar to previous reports
on BBS1 patients, with digital anomalies and obesity being the
most common systemic features noted also by others (Azari
et al., 2006; Deveault et al., 2011). PT1 and PT3 had asthma, and
PT2 also had hirsutism. Asthma is not a feature commonly consid-
ered typical of BBS. However, asthma too has been reported consis-
tently more often in BBS1 (38%) than in other BBS subtypes
(Beales et al., 1997; Deveault et al., 2011). As the role of the BBS
genes in ciliary function, including that of the respiratory trait, be-
comes increasingly understood (Shah et al., 2008), asthma and
other respiratory manifestations may become an increasingly
appreciated manifestation of BBS, and of BBS1 in particular.
Only PT1 had documented urinary tract problems (incontinence
and recurrent infections) but none had evidence of kidney abnor-malities, which are instead considered fairly typical for BBS (Anad-
oliiska & Roussinov, 1993; Campo & Aaberg, 1982; Churchill,
McManamon, & Hurley, 1981; Green et al., 1989; Hurley et al.,
1975; Iannaccone et al., 1997; O’Dea et al., 1996; Ozer et al.,
1995; Perez Perez & Barrio, 1998). The proportion of our patients
with urinary tract problems (one in three cases) is comparable to
the prevalence noted by Deveault et al. (2011), who found ultraso-
nography-demonstrated kidney abnormalities in 38% of their BBS1
patients, and by Azari et al. (2006), who reported renal problems in
30% of their BBS1 patients. This prevalence is lower than what
Deveault et al. (2011) observed in their BBS patient population as
a whole (53%). Notwithstanding the lower frequency of kidney
changes noted in BBS1, the possibility that renal dysfunction may
develop at later stages of the disease remains, and patients should
still be monitored longitudinally for signs of this problem that car-
ries such signiﬁcant morbidity risk for BBS patients (O’Dea et al.,
1996).
The cognitive and behavioral status of our three patients varied
widely. PT1 was overtly developmentally delayed, PT2 had Asper-
ger-like symptoms, and PT3 had apparently normal cognition. This
wide range of phenotypic expression at the cognitive end has been
previously noted in BBS (Barnett et al., 2002; Iannaccone et al.,
1997; Jacobson, Borruat, & Apathy, 1990) and has more recently
been conﬁrmed also for BBS1 (Azari et al., 2006; Deveault et al.,
2011).
Clinical ocular ﬁndings varied in severity, but were quite consis-
tent among the three patients and, for the most part, with previous
reports. Night blindness was a consistent ﬁnding at an early age in
all subjects. All of our BBS1 patients already had decreased visual
acuity at their baseline examinations. The severity of this visual
acuity reduction spanned over a wide range, as noted by Azari
et al. (2006) and Daniels et al. (2012). In addition, all patients expe-
rienced further acuity deterioration over time, even in the course of
the short follow-up of PT2 and PT3. Progressively deteriorating vi-
sual acuities have been consistently reported in BBS (Fulton, Han-
sen, & Glynn, 1993; Leys et al., 1988; Riise et al., 1996). Consistent
with these early reports, Deveault et al. (2011) reported progres-
sive visual loss in the majority of patients regardless of genotype.
Therefore, while it has been suggested that BBS1 patients may have
better visual acuity than other forms of BBS at presentation (Dan-
iels et al., 2012), the potential for signiﬁcant progressive acuity loss
in BBS1 patients homozygous for the M390R mutation remains.
Ophthalmoscopy consistently showed attenuation of the retinal
vasculature, RPE dropout both in the macular region and peripher-
ally, and poverty of intraretinal pigmentary deposits in all patients,
even in PT1 who was followed up for an extensive period of time.
The ﬁnding of RP sine pigmento at presentation in BBS has been
previously reported as the most common expression of retinopa-
thy in a molecularly uncharacterized series of BBS patients (Ian-
naccone et al., 1997). Intraretinal pigmentary deposits as seen in
RP tend to develop later on in the life of BBS patients (Iannaccone
et al., 1997; Riise et al., 1996), which can make the recognition of
the syndromic retinopathy phenotype and the correct formulation
of the diagnosis of BBS at referral challenging (see, e.g., cases P3, P7
and P10 in the series by Azari et al., 2006).
Imaging studies were very informative. Macular OCT ﬁndings
(Fig. 5) demonstrated normal to near normal central retinal thick-
ness in PT3 and overall thinning of the neural macular retina in
PT2. In both patients, outside of the centermost region, there was
overt loss of the photoreceptor layers (both of the ONL and the
PR-OS/IS boundary) but very good preservation of retinal lamina-
tion. The extent of overall photoreceptor compromise by OCT crite-
ria was much more severe in PT2 than in PT3, highlighting the
aforementioned variability in disease severity observed among
these three patients. Foveal photoreceptors were still fairly well
preserved also in PT2, although the PR-OS/IS boundary was clearly
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with what was observed in previous reports (Azari et al., 2006;
Deveault et al., 2011). FAF also revealed in PT3 that, while photore-
ceptors appear still in fairly good health centrally by OCT criteria,
signiﬁcant bull’s eye-shaped loss of perifoveal FAF is already pres-
ent at this stage, and that a ring of pericentral increase in FAF is
also present outside the area of FAF loss. In all patients, RPE diffuse
and, at times, discrete dropout was apparent also by ophthalmo-
scopic criteria (Fig. 2). Taken together, these ﬁndings underscore
a tendency for BBS1 linked to the M390R mutation to affect early
and signiﬁcantly the macular region and to be associated with
RPE loss. The ﬁndings of macular atrophic changes and progressive
visual acuity loss have been previously reported in BBS1 patients
(Azari et al., 2006; Deveault et al., 2011). Our longitudinal observa-
tions suggest progressive loss in central visual function also in the
relatively short term. This may be due to progressive photorecep-
tor disease, as a ciliopathy would predict and as our photographic
and SD-OCT data suggest (Figs. 2 and 5). However, the ﬁnding of
thickened RNFL may indicate that RGC/optic nerve pathology
may also contribute over time to the visual acuity deﬁcit of these
patients, as we previously reported (Iannaccone et al., 1997).
At a time when genes for BBS had yet to be cloned and SD-OCT
technology had yet to become widely available, we reported that,
compared to non-syndromic recessive RP, optic nerve involvement
represented by disk pallor and overt atrophy ascertained clinically
is common in BBS (Iannaccone et al., 1997), a ﬁnding which ap-
peared to correlate better with the degree of visual acuity loss in
BBS than macular retinal changes. In their study of BBS1 patients,
Azari et al. (2006) reported essentially normal RNFL at 1.7 mm
eccentricity from the disk by time domain OCT criteria. Our SD-
OCT disk imaging studies showed either normal or thickened RNFL,
not thinned, in both patients who could be ascertained. Of note, in
PT3, custom RNFL scan measurements within 500 lm of the lam-
ina cribrosa were necessary to reveal the thickening of the RNFL
(see Supplemental Figure), which was otherwise not apparent to
standard Cirrus disk SD-OCT scans, which are performed farther
away from the disk. RNFL thickening was not an expected observa-
tion and is of uncertain etiology. Several explanations appear pos-
sible. The RNFL thickening may represent reactive gliosis within
the retina secondary to the degenerative process. However, retinal
lamination was well preserved in the areas where increased RNFL
thickness was observed. Alternatively, the BBS1 gene product –
and those of BBS genes in general – may be important for retinal
ganglion cell (RGC) function too, and the RNFL thickening may be
an expression of this putative role. This would be consistent not
only with our previous observation of a clinical correlate between
optic nerve appearance and visual acuity (Iannaccone et al., 1997)
but also with the optic nerve dysfunction that we previously re-
ported in BBS also by visual evoked potential (VEP) criteria (Forte
et al., 1996). In addition, we have recently reported that auto-anti-
bodies recognizing RGC or optic nerve antigens are a very common
ﬁnding in patients with acquired autoimmune retinopathy (Ada-
mus et al., 2011), and these ﬁndings correlate to presence of both
changes in RNFL thickness and delayed VEPs. The development of
secondary autoimmune phenomena in RP patients and animal
models has been reported repeatedly in the past (Chant, Hecken-
lively, & Meyers-Elliott, 1985; Heckenlively, Jordan, & Aptsiauri,
1999; Radic et al., 2006; Reid, Forrester, & Campbell, 1986) and a
role for autoimmunity is becoming increasingly well appreciated
also in age-related macular degeneration (Iannaccone et al.,
2012; Morohoshi, Ohbayashi, et al., 2012, Morohoshi, Patel, et al.,
2012; Patel et al., 2005). We have observed auto-antibodies recog-
nizing RGC or optic nerve antigens in various patients certainly af-
fected with bona ﬁde RP but complicated with clinically overt,
steroid-responsive disk swelling and other inﬂammatory manifes-
tations (Iannaccone & Adamus, 2012, unpublished observation). Itis therefore possible that also the RNFL swelling seen in our BBS1
patients may have an autoimmune etiology, which may warrant
further investigation. Lastly, we cannot exclude that, in the context
of post-receptoral intraretinal remodeling and functional adapta-
tions to the ongoing disease, the thickened RNFL may reﬂect also
a compensatory mechanism at the RGC level. This may in part help
explain why so many more BBS patients than non-syndromic RP
patients develop non-recordable ERGs despite retaining well pre-
served ﬁeld limits, like PT1, and as we reported previously (Iannac-
cone et al., 1996). Whatever the cause, the possibility of RGC/optic
nerve compromise in BBS deserves further investigation, as it may
have important implications for both pharmacological and gene
therapy trials.
All of our patients demonstrated markedly reduced to non-
recordable DA rod ERGs and electronegative ERGs. This is strikingly
consistent with the observation by Azari et al. (2006). We have
been able to demonstrate that two factors contribute jointly to
the observed electronegativity: (1) exhaustion and impaired recy-
cling of the visual pigments, leading to an excessive blunting of the
rod-driven b-wave because of insufﬁcient dark adaptation, and a
progressive blunting of the b-wave response following serial bright
ﬂashes in the DA state, both phenomena that are similar to what is
seen in patients with FA and RPA (Fishman et al., 2004; Iannaccone
et al., 2007) – this observation is consistent with the depressed
ERG sensitivity observed in M390R knock-in mice (Davis et al.,
2007); (2) ON OFF bipolar cell response compromise – this is a
novel ﬁnding, appeared to represent the main cause for ERG elec-
tronegativity, and its determinants are presently uncertain. In
M390R knock-in mice, Davis et al. have reported rhodopsin mislo-
calization at the photoreceptor to bipolar cell synaptic pedicle (Da-
vis et al., 2007). It is therefore possible that BBS1 patients
experience ERG electronegativity for a proximal compromise of
this synapse. Alternatively, the electronegativity may be due to
intraretinal remodeling, as seen previously in RP (Cideciyan & Jac-
obson, 1993), though this phenomenon has not been reported in
M390R knock-in mice (Davis et al., 2007), or to a distal photorecep-
tor-to-bipolar cell synaptic defect. Azari et al. (2006) also hypoth-
esized that negative ERG waveforms represent a disease stage
rather than a primary disease feature. Consistent also with this
hypothesis, PT1 had initially markedly diminished and severely de-
layed ERGs, which progressed to an electronegative waveform
2 years later and ultimately became non-recordable. However,
PT2 and PT3 exhibited electronegative ERGs at a relatively early
disease stage. It will be of interest to see if, over time, PT2 and
PT3 experience a change in this ERG feature, and whether addi-
tional studies on the M390R knock-in mice can help shed light
on this novel ﬁnding.
In summary, our investigation conﬁrms a number of previously
documented features in BBS1 patients, and expands our under-
standing of the BBS1 ophthalmic phenotypic spectrum in M390R
homozygotes by reporting novel ﬁndings which include electro-
negative LA ERG with ON OFF bipolar cell response compromise
and increased RNFL thickness. In consideration of the high preva-
lence of the M390R mutation in the BBS population and the recent
evidence that treatment with TUDCA prevented obesity and pre-
served ERG b-waves and ONL thickness in the aforementioned
Bbs1 knock-in M390R mice (Drack et al., 2011), increasing our
understanding of BBS1 retinal, RPE and optic nerve pathology in
patients homozygous for the M390R mutation is of great potential
relevance to forthcoming treatment trial opportunities for patients
affected by this otherwise lawful condition.
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